Skyward Specialty schedules third-quarter 2026 earnings call
Bitget2026/10/08 12:33Skyward Specialty Insurance Group will release Q3 2026 earnings after the market close on Nov. 5, 2026. Results will post at investors.skywardinsurance.com/ under Quarterly Results. Earnings call set for Nov. 6, 2026 at 10:00 a.m. ET to discuss the quarter’s financial results. Live webcast available via investors.skywardinsurance.com/ under Events & Presentations. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skyward Specialty Insurance Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610080830PRIMZONEFULLFEED9841944) on October 08, 2026, and is solely responsible for the information contained therein.
- Skyward Specialty Insurance Group will release Q3 2026 earnings after the market close on Nov. 5, 2026.
- Results will post at investors.skywardinsurance.com/ under Quarterly Results.
- Earnings call set for Nov. 6, 2026 at 10:00 a.m. ET to discuss the quarter’s financial results.
- Live webcast available via investors.skywardinsurance.com/ under Events & Presentations.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
